CSIMarket Company Name, Ticker, Customers, else..
 
Mbx Biosciences Inc   (NASDAQ: MBX)
 
Price: $57.3300 $-0.21 -0.365%
Day's High: $57.66999816894531 Week Perf: -0.97 %
Day's Low: $ 56.55 30 Day Perf: -9 %
Volume (M): 23,891 52 Wk High: $ 72.64
Volume (M$): $ 0 52 Wk Avg: $38.88
Open: $57.27 52 Wk Low: $12.94



 Market Capitalization (Millions $) 2,734
 Shares Outstanding (Millions) 48
 Employees 63
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -104
 Cash Flow (TTM) (Millions $) 6
 Capital Exp. (TTM) (Millions $) 3

Business Description


The company conducts research and development programs, preclinical studies, and clinical trials to develop product candidates for treating specific diseases and conditions. It focuses on optimizing the pharmacokinetic and pharmacologic properties of its product candidates and advancing them through clinical studies, manufacturing, and regulatory approval processes.


   Company Address: 11711 N. Meridian Street Carmel 46032 IN
   Company Phone Number: 659-0200   Stock Exchange / Ticker: NASDAQ MBX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Clinical Study

Advancing Treatment Paradigms MBX Biosciences Unveils Promising Phase 2 Results for Canvuparatide in Hypoparathyroidi...

Published Mon, Sep 22 2025 3:22 AM UTC

MBX Biosciences, a biopharmaceutical innovator specializing in precision peptide therapies, is positioned at the forefront of endocrine and metabolic disorder treatments. This article discusses the upcoming topline results from its Phase 2 trial of canvuparatide for hypoparathyroidism (HP), alongside the company’s recent successes in related clinical trials aimed at adva...
Clinical Study

MBX Biosciences Advances Hypoparathyroidism Treatment with Successful Enrollment in Phase 2 Avail Trial of Canvuparat...

Published Fri, Jun 20 2025 5:28 PM UTC

Advancement in Hypoparathyroidism Treatment: MBX Biosciences’ Phase 2 Avail Trial of MBX 2109 Concludes Enrollment MBX Biosciences has reached a significant milestone in the development of its promising treatment for hypoparathyroidism with the completion of participant enrollment in the Phase 2 Avail trial for MBX 2109, also known as Canvuparatide. With the number of enro...
Management Changes

MBX Biosciences Strengthens Leadership and Unveils Innovative Phase 2 Trial for Hypoparathyroidism Treatment

Published Wed, Mar 5 2025 1:01 PM UTC

In the evolving landscape of biopharmaceuticals, MBX Biosciences, Inc. (NASDAQ: MBX) continues to assert its commitment to addressing unmet medical needs through strategic leadership appointments and groundbreaking clinical research. The company recently announced the appointment of Chatan Charan, Ph.D. as the Senior Vice President of Pharmaceutical Development and Chemistry...
Clinical Study

MBX 2109 Phase 2 Avail Hypoparathyroidism Trial Rationale and Design Presented at ASBMR 2024

Published Mon, Sep 30 2024 12:00 PM UTC

In a significant development for the treatment of hypoparathyroidism (HP), MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company, presented compelling data concerning the rationale and design of its Phase 2 Avail trial for the investigational drug MBX 2109. The presentation was featured at the American Society for Bone and Mineral Research (ASBMR) 2...
Shares

MBX Biosciences' IPO Surges with $187.7 Million Raised, Paving the Way for Next-Gen Precision Peptide Therapies,

Published Mon, Sep 16 2024 8:05 PM UTC


CARMEL, Ind. Sept. 16, 2024 MBX Biosciences, Inc. (Nasdaq: MBX) has successfully concluded its previously announced upsized initial public offering (IPO), closing the sale of 11,730,000 shares of its common stock at a public offering price of $16.00 per share. This offering not only reflects a robust demand for the company’s stock but also includes the full exercise...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book 6.68
PEG (TTM) -

Financial Strength Current
Quick Ratio 33.1
Working Capital Ratio 33.62
Leverage Ratio (MRQ) 0.06
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.51 $
Revenues (TTM) -
Cash Flow (TTM) 0.12 $
Cash 16.42 $
Book Value 8.59 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -1,655,429
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.